This program is cosupported by educational grants from Astellas and Pfizer; Bayer HealthCare Pharmaceuticals Inc.; and Seagen Inc.
This activity is supported by educational grants from Astellas and Pfizer and Bayer HealthCare Pharmaceuticals Inc.
Oncology NPs, PAs, and nurses
Summarize available and emerging agents across the continuum of prostate cancer
Apply efficacy and safety evidence, molecular testing, and guideline recommendations to develop treatment plans for patients with prostate cancer
Implement strategies to identify and manage adverse events associated with treatment of prostate cancer
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
Dr McKay: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento Therapeutics, and Tempus.
Ms Sims: consulting fees: Coloplast.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
The estimated time to complete this activity is 0.50 hours.
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.
Release date: February 10, 2022
Expiration date: February 9, 2023
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until February 9, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA Course Advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.
This program has been made available online.